Catheter
FDA approves DefenCath for adults with kidney failure on chronic hemodialysis
The FDA has approved DefenCath, a catheter lock solution of taurolidine and heparin by CorMedix Inc., for adults with kidney failure on chronic hemodialysis, according to a press release.
Racial, ethnic differences seen in arteriovenous access after hemodialysis initiation
PHILADELPHIA — Racial and ethnic differences exist in arteriovenous access use in patients 1 year after hemodialysis initiation, according to data presented at ASN Kidney Week.
Catheter-directed thrombolysis for PE confers less bleeding vs. mechanical thrombectomy
SAN FRANCISCO — In the REAL-PE study of a real-world population of patients with pulmonary embolism, catheter-directed thrombolysis was associated with reduced risk for major bleeding compared with mechanical thrombectomy.
Catheter for mapping of complex cardiac arrhythmias launched
Biosense Webster announced the U.S. launch of a catheter to help electrophysiologists with mapping complex cardiac arrhythmias.
Transfusion policies may negatively affect outcomes after central catheter placement
Withholding prophylactic platelet transfusion before placement of a central venous catheter in patients with severe thrombocytopenia resulted in more catheter-related bleeding events, results of a randomized noninferiority trial showed.
In nephrology, the conundrum regarding vascular access choice continues
“Vascular access is the Achilles’ heel of dialysis therapy.”
Higher plasma omeintin-1 level correlates with reduced subsequent hospital admission, stay
Among patients on incident peritoneal dialysis, higher plasma omeintin-1 level quartile correlates with reduced subsequent hospital admissions and shorter hospital stays, according to data published in Kidney Medicine.
FDA designates recall of central venous access, catheter kits as class I
The FDA announced that Teleflex and Arrow International LLC are recalling both the Arrow MAC Two-Lumen Central Venous Access Kit and the Arrow Pressure Injectable Arrowg+ard Blue Plus Three-Lumen Central Venous Catheter Kit.
Meta-analysis: Rhythm control with catheter ablation ‘preferred treatment’ in AF, HFrEF
In patients with atrial fibrillation and concurrent HF with reduced ejection fraction, catheter ablation significantly reduced all-cause mortality compared with medical therapy, according to a new meta-analysis.
VIDEO: Transition costs are high when patients switch from PD to HHD
BOSTON — In this video from the National Kidney Foundation Spring Clinical Meetings, Eric D. Weinhandl, PhD, MS, talks about the hidden costs in helping patients transition from peritoneal dialysis to home hemodialysis.